Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.

Abstract

BACKGROUND For decades, a broadly effective vaccine against serogroup B Neisseria meningitidis (MenB) has remained elusive. Recently, a four-component recombinant vaccine (4CMenB) has been developed and is now approved in Europe, Canada, Australia and some Latin American countries. This phase III, randomized study evaluated the lot consistency, early immune… (More)
DOI: 10.1016/j.vaccine.2015.06.103

Topics

5 Figures and Tables

Cite this paper

@article{Perrett2015ImmuneRT, title={Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.}, author={Kirsten P. Perrett and Jodie McVernon and Peter Richmond and Helen Marshall and Matthias Nissen and Allison August and Sandra R Percell and Daniela Toneatto and Terry Nolan}, journal={Vaccine}, year={2015}, volume={33 39}, pages={5217-24} }